{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:09:35Z","timestamp":1793045375340,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tolvaptan is the first disease-modifying drug proven to slow eGFR decline in high-risk patients with ADPKD. However, barriers from the patient perspective to its use in real-life settings have not been systemically examined in a large cohort. This was a\u00a0single-center, retrospective study of 523 existing or new patients with ADPKD followed at the Center for Innovative Management of PKD in Toronto, Ontario, between January 1, 2016 to December 31, 2018. All patients underwent clinical assessment including total kidney volume measurements and Mayo Clinic Imaging Class (MCIC). Those who were deemed to be at high risk were offered tolvaptan with their preference (yes or no) and reasons for their choices recorded. Overall, 315\/523 (60%) patients had MCIC 1C-1E; however, only 96 (30%) of them were treated with tolvaptan at their last follow-up. Among these high-risk patients, those not treated versus treated with tolvaptan were more likely to have a higher eGFR (82\u2009\u00b1\u200926 vs. 61\u2009\u00b1\u200927\u00a0ml\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>), CKD stages 1\u20132 (79% vs. 41%), and MCIC 1C (63% vs. 31%). The most common reasons provided for not taking tolvaptan were lifestyle preference related to the aquaretic effect (51%), older age\u2009\u2265\u200960 (12%), and pregnancy\/family planning (6%). In this real-world experience, at least 60% of patients with ADPKD considered to be at high risk for progression to ESKD by imaging were not treated with tolvaptan; most of them had early stages of CKD with well-preserved eGFR and as such, were\u00a0prime targets for tolvaptan therapy to slow disease progression. Given that\u00a0the most common reason for tolvaptan refusal was the concern for intolerability of the aquaretic side-effect, strategies to mitigate this  may help to reduce this barrier to tolvaptan therapy.<\/jats:p>","DOI":"10.1038\/s41598-023-48638-9","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T18:02:41Z","timestamp":1702576961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Real-life use of tolvaptan in ADPKD: a retrospective analysis of a large Canadian cohort"],"prefix":"10.1038","volume":"13","author":[{"given":"Luca","family":"Calvaruso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedram","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemah","family":"Nasri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saima","family":"Khowaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bill","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirreza","family":"Haghighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korosh","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"York","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"key":"48638_CR1","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1681\/ASN.2018050493","volume":"29","author":"MB Lanktree","year":"2018","unstructured":"Lanktree, M. B. et al. Prevalence estimates of polycystic kidney and liver disease by population sequencing. J. Am. Soc. Nephrol. 29, 2593\u20132600. https:\/\/doi.org\/10.1681\/ASN.2018050493 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"48638_CR2","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/s0272-6386(83)80044-4","volume":"2","author":"CG Iglesias","year":"1983","unstructured":"Iglesias, C. G. et al. Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935\u20131980. Am. J. Kidney Dis. 2, 630\u2013639. https:\/\/doi.org\/10.1016\/s0272-6386(83)80044-4 (1983).","journal-title":"Am. J. Kidney Dis."},{"key":"48638_CR3","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/ki.2014.120","volume":"86","author":"EM Spithoven","year":"2014","unstructured":"Spithoven, E. M. et al. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney Int. 86, 1244\u20131252. https:\/\/doi.org\/10.1038\/ki.2014.120 (2014).","journal-title":"Kidney Int."},{"key":"48638_CR4","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/S0140-6736(15)60907-2","volume":"385","author":"AC Ong","year":"2015","unstructured":"Ong, A. C. et al. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet 385, 1993\u20132002. https:\/\/doi.org\/10.1016\/S0140-6736(15)60907-2 (2015).","journal-title":"Lancet"},{"key":"48638_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2015.59","volume":"88","author":"AB Chapman","year":"2015","unstructured":"Chapman, A. B. et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 88, 17\u201327. https:\/\/doi.org\/10.1038\/ki.2015.59 (2015).","journal-title":"Kidney Int"},{"key":"48638_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/s0140-6736(98)03495-3","volume":"353","author":"N Hateboer","year":"1999","unstructured":"Hateboer, N. et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 353, 103\u2013107. https:\/\/doi.org\/10.1016\/s0140-6736(98)03495-3 (1999).","journal-title":"Lancet"},{"key":"48638_CR7","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1681\/ASN.2006121387","volume":"18","author":"S Rossetti","year":"2007","unstructured":"Rossetti, S. et al. Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 18, 2143\u20132160. https:\/\/doi.org\/10.1681\/ASN.2006121387 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"48638_CR8","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1681\/ASN.2015050583","volume":"27","author":"CM Heyer","year":"2016","unstructured":"Heyer, C. M. et al. Predicted mutation strength of nontruncating PKD1 mutations aids genotype-phenotype correlations in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol 27, 2872\u20132884. https:\/\/doi.org\/10.1681\/ASN.2015050583 (2016).","journal-title":"J. Am. Soc. Nephrol"},{"key":"48638_CR9","doi-asserted-by":"publisher","unstructured":"Cornec-Le Gall, E. et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol 24, 1006\u20131013 (2013). DOI:https:\/\/doi.org\/10.1681\/ASN.2012070650","DOI":"10.1681\/ASN.2012070650"},{"key":"48638_CR10","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1681\/ASN.2015060648","volume":"27","author":"YH Hwang","year":"2016","unstructured":"Hwang, Y. H. et al. Refining genotype-phenotype correlation in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 27, 1861\u20131868. https:\/\/doi.org\/10.1681\/ASN.2015060648 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"48638_CR11","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/nm935","volume":"9","author":"VH Gattone","year":"2003","unstructured":"Gattone, V. H., Wang, X., Harris, P. C. & Torres, V. E. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat. Med. 9, 1323\u20131326. https:\/\/doi.org\/10.1038\/nm935 (2003).","journal-title":"Nat. Med."},{"key":"48638_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nm1004","volume":"10","author":"VE Torres","year":"2004","unstructured":"Torres, V. E. et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat. Med. 10, 363\u2013364. https:\/\/doi.org\/10.1038\/nm1004 (2004).","journal-title":"Nat. Med."},{"key":"48638_CR13","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407\u20132418. https:\/\/doi.org\/10.1056\/NEJMoa1205511 (2012).","journal-title":"N. Engl. J. Med."},{"key":"48638_CR14","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres, V. E. et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N. Engl. J. Med. 377, 1930\u20131942. https:\/\/doi.org\/10.1056\/NEJMoa1710030 (2017).","journal-title":"N. Engl. J. Med."},{"key":"48638_CR15","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2215\/CJN.06300615","volume":"11","author":"VE Torres","year":"2016","unstructured":"Torres, V. E. et al. Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: Results from the TEMPO 3:4 trial. Clin. J. Am. Soc. Nephrol. 11, 803\u2013811. https:\/\/doi.org\/10.2215\/CJN.06300615 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"48638_CR16","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/ndt\/gfab312","volume":"37","author":"RU M\u00fcller","year":"2022","unstructured":"M\u00fcller, R. U. et al. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: Consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. Nephrol. Dial. Transplant 37, 825\u2013839. https:\/\/doi.org\/10.1093\/ndt\/gfab312 (2022).","journal-title":"Nephrol. Dial. Transplant"},{"key":"48638_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1681\/ASN.2008050507","volume":"20","author":"Y Pei","year":"2009","unstructured":"Pei, Y. et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J. Am. Soc. Nephrol. 20, 205\u2013212. https:\/\/doi.org\/10.1681\/ASN.2008050507 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"48638_CR18","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1681\/ASN.2014030297","volume":"26","author":"Y Pei","year":"2015","unstructured":"Pei, Y. et al. Imaging-based diagnosis of autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 26, 746\u2013753. https:\/\/doi.org\/10.1681\/ASN.2014030297 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"48638_CR19","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1097\/00004728-200007000-00019","volume":"24","author":"KT Bae","year":"2000","unstructured":"Bae, K. T., Commean, P. K. & Lee, J. Volumetric measurement of renal cysts and parenchyma using MRI: Phantoms and patients with polycystic kidney disease. J. Comput. Assist. Tomogr. 24, 614\u2013619. https:\/\/doi.org\/10.1097\/00004728-200007000-00019 (2000).","journal-title":"J. Comput. Assist. Tomogr."},{"key":"48638_CR20","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1046\/j.1523-1755.2003.00185.x","volume":"64","author":"AB Chapman","year":"2003","unstructured":"Chapman, A. B. et al. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int. 64, 1035\u20131045. https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00185.x (2003).","journal-title":"Kidney Int."},{"key":"48638_CR21","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"MV Irazabal","year":"2015","unstructured":"Irazabal, M. V. et al. Imaging classification of autosomal dominant polycystic kidney disease: A simple model for selecting patients for clinical trials. J. Am. Soc. Nephrol. 26, 160\u2013172. https:\/\/doi.org\/10.1681\/ASN.2013101138 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"48638_CR22","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ekir.2017.01.003","volume":"2","author":"RD Perrone","year":"2017","unstructured":"Perrone, R. D. et al. Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease. Kidney Int. Rep. 2, 442\u2013450. https:\/\/doi.org\/10.1016\/j.ekir.2017.01.003 (2017).","journal-title":"Kidney Int. Rep."},{"key":"48638_CR23","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1038\/s41598-022-24104-w","volume":"13","author":"IA Iliuta","year":"2023","unstructured":"Iliuta, I. A. et al. Atypical polycystic kidney disease as defined by imaging. Sci. Rep. 13, 2952. https:\/\/doi.org\/10.1038\/s41598-022-24104-w (2023).","journal-title":"Sci. Rep."},{"key":"48638_CR24","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1681\/ASN.2018060590","volume":"29","author":"FT Chebib","year":"2018","unstructured":"Chebib, F. T. et al. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J. Am. Soc. Nephrol. 29, 2458\u20132470. https:\/\/doi.org\/10.1681\/ASN.2018060590 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"48638_CR25","doi-asserted-by":"publisher","first-page":"F1008","DOI":"10.1152\/ajprenal.00102.2016","volume":"310","author":"JD Klein","year":"2016","unstructured":"Klein, J. D. et al. Metformin, an AMPK activator, stimulates the phosphorylation of aquaporin 2 and urea transporter A1 in inner medullary collecting ducts. Am. J. Physiol. Renal Physiol. 310, F1008-1012. https:\/\/doi.org\/10.1152\/ajprenal.00102.2016 (2016).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"48638_CR26","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.88409","author":"O Efe","year":"2016","unstructured":"Efe, O., Klein, J. D., LaRocque, L. M., Ren, H. & Sands, J. M. Metformin improves urine concentration in rodents with nephrogenic diabetes insipidus. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.88409 (2016).","journal-title":"JCI Insight"},{"key":"48638_CR27","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJM196004142621501","volume":"262","author":"JD Crawford","year":"1960","unstructured":"Crawford, J. D., Kennedy, G. C. & Hill, L. E. Clinical results of treatment of diabetes insipidus with drugs of the chlorothiazide series. N. Engl. J. Med. 262, 737\u2013743. https:\/\/doi.org\/10.1056\/NEJM196004142621501 (1960).","journal-title":"N. Engl. J. Med."},{"key":"48638_CR28","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2215\/CJN.11260821","volume":"17","author":"BJ Kramers","year":"2022","unstructured":"Kramers, B. J. et al. Effects of hydrochlorothiazide and metformin on aquaresis and nephroprotection by a vasopressin V2 receptor antagonist in ADPKD: A randomized crossover trial. Clin. J. Am. Soc. Nephrol. 17, 507\u2013517. https:\/\/doi.org\/10.2215\/CJN.11260821 (2022).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"48638_CR29","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2215\/CJN.0000000000000049","volume":"18","author":"M Trillini","year":"2023","unstructured":"Trillini, M. et al. Effects of octreotide-long-acting release added-on tolvaptan in patients with autosomal dominant polycystic kidney disease: Pilot, randomized, placebo-controlled, cross-over trial. Clin. J. Am. Soc. Nephrol. 18, 223\u2013233. https:\/\/doi.org\/10.2215\/CJN.0000000000000049 (2023).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"48638_CR30","unstructured":"NICE. Tolvaptan for treating autosomal dominant polycystic kidney disease, https:\/\/www.nice.org.uk\/guidance\/ta358 (2015)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48638-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48638-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48638-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T18:07:51Z","timestamp":1702577271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48638-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["48638"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-48638-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,14]]},"assertion":[{"value":"16 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.P. has received compensation for participation in advisory boards for Otsuka, Maze Therapeutic, and Sanofi-Genzyme. All remaining authors have nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22257"}}